Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

336.89USD
18 Sep 2018
Change (% chg)

$2.49 (+0.74%)
Prev Close
$334.40
Open
$333.46
Day's High
$338.46
Day's Low
$332.49
Volume
510,248
Avg. Vol
610,723
52-wk High
$388.67
52-wk Low
$249.24

Select another date:

Tue, Aug 14 2018

Photo

Biogen's pricey muscle drug Spinraza too costly for Britain

LONDON Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.

Biogen's pricey muscle drug Spinraza too costly for Britain

LONDON Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.

Biogen's pricey muscle drug Spinraza too costly for Britain

LONDON, Aug 14 Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.

Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study

CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.

Biogen easily tops Street estimates on Spinraza sales, raises forecast

Biogen Inc reported far better-than-expected second quarter profit on Tuesday, driven by strong demand of its Spinraza muscle disease treatment, and the U.S. biotech company raised its full-year profit forecast.

REFILE-UPDATE 3-Biogen easily tops Street estimates on Spinraza sales, raises forecast

* Late-stage trials for Alzheimer's drug aducanumab fully enrolled

Biogen quarterly sales rise 9 pct

July 24 Biogen Inc reported a 9 percent rise in quarterly revenue on Tuesday, helped by demand for its spinal muscular atrophy drug Spinraza.

Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar

Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose. | Video

UPDATE 1-Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar

* Eisai shares up as much as 14.6 pct in morning Tokyo trading

Biogen's Alzheimer's drug succeeds in mid-stage trial

July 5 Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.

Select another date: